[
  {
    "page": 9,
    "table": "Continue to seek approvals for our medicines globally\nSpearhead multi-stakeholder solutions that empower patients and disrupt\nsystemic access barriers by 2025\nEstablish and launch the BeiGene Foundation"
  },
  {
    "page": 10,
    "table": "Global gender parity at the VP level and above by 2030\n50% improvement in workforce diversity (underrepresented groups)\ncompany-wide at management levels in the U.S. by 2030\nContinue to address the composition of the Board of Directors\nfor gender and U S underrepresented groups\nMaintain colleague engagement scores globally versus 2022 engagement\nscores with a stretch goal of +3% for the 2024 engagement survey\nImprove work-life balance survey scores by 3%, with a stretch goal of 5% in 2023\nEngage colleagues by 10,000 hours of global volunteerism by 2023\nExpand volunteer paid time-off policy"
  },
  {
    "page": 11,
    "table": "Set a quantitative Scopes 1 and 2 emissions goal by 2024\nSet a quantitative Scope 3 emissions goal by 2025. To advance this goal,\nengage with top suppliers most likely to contribute to Scope 3 emissions*"
  },
  {
    "page": 11,
    "table": "Implement a third-party supplier risk management program in 2023"
  },
  {
    "page": 12,
    "table": "Engage colleagues in 10,000 hours of global volunteerism in 2024, with a stretch goal of 20,000 hours\nReduce our Scope 1 and 2 emissions by 25% per unit for our internally manufactured\ncommercial product by 2026 (with 2021 as a base year)\nDevelop a strategy to align with the United Nations Global Compactâ€™s guidance on human rights by 2025\nDevelop a plan to better align key privacy performance metrics with RB&S practices by 2025"
  }
]